Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D
Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — Vaccine component.